Home > Press > Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda
 |
Abstract:
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the collaboration and license agreement between Arrowhead and Takeda Pharmaceutical Company Limited announced on October 8, 2020, has now closed.
Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda
Pasadena. CA | Posted on November 27th, 2020
Closing of the transaction was contingent on completion of review under antitrust laws, including the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 in the U.S.
####
About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowheads RNAi-based therapeutics leverage this natural pathway of gene silencing.
For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company’s email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts .
Safe Harbor Statement under the Private Securities Litigation Reform Act:
This news release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.
For more information, please click here
Contacts:
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400
Investors:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578
www.lifesciadvisors.com
Media:
LifeSci Communications, LLC
Josephine Belluardo, Ph.D.
646-751-4361
www.lifescicommunications.com
Copyright © Arrowhead Pharmaceuticals, Inc.
If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Bookmark:
News and information
CsPbBrI2 perovskites with low energy loss for high-performance indoor and outdoor photovoltaics December 1st, 2020
One-way street for electrons: Scientists observe directed energy transport between neighbouring molecules in a nanomaterial November 27th, 2020
New insights into memristive devices by combining incipient ferroelectrics and graphene November 27th, 2020
Nanomedicine
An ionic forcefield for nanoparticles: Tunable coating allows hitch-hiking nanoparticles to slip past the immune system to their target November 27th, 2020
Arrowhead Pharmaceuticals Reports Fiscal 2020 Year End Results November 23rd, 2020
Arrowhead Interim Clinical Data Demonstrate ARO-AAT Treatment Improved Multiple Biomarkers of Alpha-1 Liver Disease November 13th, 2020
Announcements
CsPbBrI2 perovskites with low energy loss for high-performance indoor and outdoor photovoltaics December 1st, 2020
One-way street for electrons: Scientists observe directed energy transport between neighbouring molecules in a nanomaterial November 27th, 2020
New insights into memristive devices by combining incipient ferroelectrics and graphene November 27th, 2020
Patents/IP/Tech Transfer/Licensing
HORIBA Medical and CEA-Leti Strengthen Their Partnership to Develop Tomorrows Diagnostics at the Point of Care July 21st, 2020
New green technology from UMass Amherst generates electricity ‘out of thin air’ Renewable device could help mitigate climate change, power medical devices February 17th, 2020
The Wave of the Future: Researchers achieve first successful generation and detection of pure spin currents in antiferromagnetic materials January 29th, 2020
Nanobiotechnology
An ionic forcefield for nanoparticles: Tunable coating allows hitch-hiking nanoparticles to slip past the immune system to their target November 27th, 2020
Arrowhead Pharmaceuticals Reports Fiscal 2020 Year End Results November 23rd, 2020
Arrowhead Interim Clinical Data Demonstrate ARO-AAT Treatment Improved Multiple Biomarkers of Alpha-1 Liver Disease November 13th, 2020
New-Contracts/Sales/Customers
Veeco Announces Aledia Order of 300mm MOCVD Equipment for microLED Displays: Propel Platform First 300mm System with EFEM Designed for Advanced Display Applications October 20th, 2020
GREENWAVES TECHNOLOGIES Announces Next Generation GAP9 Hearables Platform Using GLOBALFOUNDRIES 22FDX Solution October 16th, 2020
Oxford Instruments Supplies HLJ Technology Co. Ltd., with Plasma Etch and Deposition Solutions for the fabrication of VCSELS on 6 inch wafers October 3rd, 2019
